Bortezomib for previously untreated multiple myeloma.

about

The choice of regimens based on bortezomib for patients with newly diagnosed multiple myeloma

P2860

Q28539605-96BFF0F5-A4B5-4973-AE04-C6601783E53A

P2860

Bortezomib for previously untreated multiple myeloma.

Item

http://www.wikidata.org/entity/Q37908155

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Bortezomib for previously untreated multiple myeloma.

@en

type

Item

label

Bortezomib for previously untreated multiple myeloma.

@en

prefLabel

Bortezomib for previously untreated multiple myeloma.

@en

P1476

Bortezomib for previously untreated multiple myeloma.

@en

P2093

Javier de la Rubia

http://www.w3.org/2001/XMLSchema#string

Mónica Roig

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2005

Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients.

A phase 2 study of bortezomib in relapsed, refractory myeloma.

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies.

Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.

A practical update on the use of bortezomib in the management of multiple myeloma.

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.

Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics.

Use of bortezomib as induction therapy prior to stem cell transplantation in frontline treatment of multiple myeloma: impact on stem cell harvesting and engraftment.

P304

381-398

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/EHM.11.38

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21801129

http://www.w3.org/2001/XMLSchema#string

Bortezomib for previously untreated multiple myeloma.

about

P2860

P2860

Bortezomib for previously untreated multiple myeloma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698